- Home
- XXI vs LIVN Comparison
XXI vs LIVN Comparison
Compare XXI & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$66.56
Company Overview
Basic Information| Metric | XXI | LIVN |
|---|---|---|
| Founded | 2025 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.5B |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | XXI | LIVN |
|---|---|---|
| Price | $6.51 | $66.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $67.38 |
| AVG Volume (30 Days) | ★ 1.2M | 615.0K |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,348,962,000.00 |
| Revenue This Year | N/A | $12.25 |
| Revenue Next Year | N/A | $6.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 8.63 |
| 52 Week Low | $5.88 | $32.48 |
| 52 Week High | $59.75 | $67.92 |
Technical Indicators
Market Signals| Indicator | XXI | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 25.33 | 59.28 |
| Support Level | $5.88 | $64.23 |
| Resistance Level | $8.64 | $67.20 |
| Average True Range (ATR) | 0.55 | 1.81 |
| MACD | -0.20 | 0.10 |
| Stochastic Oscillator | 13.04 | 68.65 |
Price Performance
Historical Comparison XXI
LIVN
About XXI Twenty One Capital Inc. Class A Common Stock
Twenty One Capital Inc has no operation history.
About LIVN LivaNova PLC
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.